The next generation of non-competitive pharmacological chaperones

Startup

ABOUT MINORYX

      
At Minoryx, we are committed to finding innovative treatments for life threatening rare diseases.
 

We are currently focused on Inborn Errors of Metabolism, a group of rare diseases of genetic origin with highly unmet medical need. Such diseases are life threatening and highly debilitating, usually with neurological manifestations and affect most severely the pediatric population.

We develop a new generation of pharmacological chaperones, a small molecule drug class aimed to restore protein functionality and which offer one of the most promising approaches to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved on developing small molecule drugs which counteract the cellular dysfunctions originated by the corresponding protein deficiency.
    
Organization founded in Spain.

SECTORS - INDUSTRY

LOCATIONS

PROFILE STRENGTH

This profile looks great, do you want to share it with the world?
BEGINNER
ADVANCED
REAL PRO

This website uses cookies to allow us to see how the site is used. If you continue to use this site we will assume that you are happy with this. If you want to use the site without cookies or would like to know more, you can do that. here .